Ankit Mahadevia, Director at Spero Therapeutics, Inc. (SPRO), sold 127,590 shares at $1.37 ($175K) on 2024-02-02, disclosed to the SEC on 2024-02-05.
Open-market sale of $175k SPRO by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.37 | 63,795 | $87K | 50.0% |
| 2 | $1.37 | 63,795 | $87K | 50.0% |
| Total | $1.37 avg | 127,590 | $175K | 100% |
| Filing → |
| SPRO | SELL | 2024-08-29 | $8K | — | Filing → |
| SPRO | SELL | 2023-08-30 | $11K | — | Filing → |
| SPRO | SELL | 2023-02-06 | $22K | — | Filing → |